Abstract 187P
Background
Chemoradiation in Stomach is indicated in patients who do not receive perioperative chemotherapy. While contouring the organs at risk in CRT of stomach spleen is not considered as the organ at risk (OARS). Leukopenia is also seen very commonly during the CRT of stomach. We are trying to correlate the grade of leukopenia to the dose received by spleen during CRT of stomach. The primary aim of this study -To determine the dose achieved by Spleen during the Post Operative Adjuvant Radiotherapy of Carcinoma Stomach. Correlate the dose achieved to the weekly blood counts (Grade 3 Hematological Toxicity).
Methods
Patients attending Kasturba Medical College OPD diagnosed with Carcinoma Stomach and planned for Adjuvant Chemoradiation were considered for the study. We analyzed 42 patients from the Jan 2018 to December 2018. The Dosimetric and Volumetric Parameters were calculated for Spleen. The patients in our study underwent Upfront Gastrectomy (Total/Partial) and received 2 cycles of Adjuvant Chemotherapy (CAPOX). Then referred for adjuvant Chemoradiation.
Results
The Mean dose achieved was 36 Gy. The range of dose received by the spleen ranged from 35Gy- 45 Gy. The doses were high when splenic nodes were irradiated. 18 patients (42%) presented with Grade 3 Hematological toxicity( Leukopenia). 15 patients (35%) could not receive Concurrent Chemotherapy in view of non recovery of Hematological Toxicities.
Conclusions
From our study we found that Spleen is a Dose limiting Structure while planning the Adjuvant Post Operative Radiotherapy in Carcinoma Stomach. The dose received by spleen can be correlated with the grade of Leukopenia in patients receiving adjuvant CRT for Carcinoma Stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Umesh Velu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract